<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661895</url>
  </required_header>
  <id_info>
    <org_study_id>05-13859</org_study_id>
    <secondary_id>05-13589</secondary_id>
    <nct_id>NCT00661895</nct_id>
  </id_info>
  <brief_title>Black Education and Treatment of Hypertension (BEAT HTN)</brief_title>
  <acronym>BEAT</acronym>
  <official_title>Black Education and Treatment of Hypertension (BEAT HTN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trials have yet to test the adequacy of HTN control in African Americans (AA) when
      both control and intervention groups are given free antihypertensive medications and are
      involved in usual versus intensive intervention strategies. Because of this, it has not yet
      been determined whether the method of prescribing antihypertensive medications according to
      JNC 7 guidelines is more, less, or equally as effective as prescribing antihypertensive
      medications and providing intensive behavioral and clinical interventions. Knowledge in this
      area of HTN treatment should better able medical and health practitioners to help their AA
      subjects control HTN. The BEAT Hypertension Clinic will evaluate this method of HTN control
      by proposing a program that will evaluate the difference in HTN control among subjects
      receiving usual care and free medications and subjects also receiving free medications, but
      additionally being treated in a clinic that operates in a more intensive manner in
      relationship to patient behavior modification, patient-clinician interactions, and physical
      and social environments. At the conclusion of the study, the BEAT Hypertension Clinic
      investigators will report findings and help to answer the question of whether medication
      alone or medication combined with intensive behavioral and clinical treatment is more
      effective in HTN control in the AA population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving Blood Pressure Goals</measure>
    <time_frame>3 month intervals</time_frame>
    <description>Percentage of subjects who achieved JNC-VII defined blood pressure goals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New Onset Diabetes Mellitus</measure>
    <time_frame>3 month intervals</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group subjects will receive education and assistance from a Community Health Center or Cardiac Center nurse practitioner or physician, health educator, dietitian, social worker, and Cardiac Center-trained community members called Community Health Advocates (CHAs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide 25 mg tablets</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril and Hydrochlorothiazide</intervention_name>
    <description>L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine XL</intervention_name>
    <description>30 mg extended release tablets, 60 mg extended release tablets</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol tartrate</intervention_name>
    <description>50 mg tablets &amp; 100 mg tablets</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Lopressor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>50 mg tablet</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>80 mg tablets &amp; 160 mg tablet</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <description>4 mg tablets</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>0.2 mg tablets</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydralazine</intervention_name>
    <description>50 mg tablets</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol succinate</intervention_name>
    <description>50 mg tablet &amp; 100 mg tablet</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Toprol XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>5 mg tablets &amp; 10 mg tablets</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Norvasc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Demographics: men or women of self-declared African-American heritage between 25 and
             80 years of age residing in the Omaha, Nebraska metropolitan area

          2. History of documented uncontrolled (treated or untreated) hypertension (HTN) as
             defined by JNC 7 guidelines

          3. Study eligibility will be based on the subject's current blood pressure control based
             on the average of two seated blood pressure measurements at two consecutive clinic
             visits at least one week apart

               1. Untreated subjects with elevated blood pressure (&gt; 140/90 mmHg or &lt; 130/80 mmHg
                  for diabetics)

               2. Subjects treated with antihypertensive therapy whose blood pressure does not meet
                  current JNC 7 guidelines (&lt; 140/90 mmHg for non-diabetics and &lt; 130/80 mmHg for
                  diabetics)

        Exclusion Criteria:

          1. Myocardial infarction or stroke in the previous 6 months

          2. Symptomatic heart failure or a left ventricular ejection fraction &lt; 35%

          3. Angina pectoris in the prior six months

          4. Coronary revascularization procedure in the prior 6 months

          5. Renal insufficiency defined as a serum creatinine &gt; 2 mg/dl

          6. Illicit drug or alcohol abuse in the prior 6 months

          7. Dementia or other organic brain disease

          8. Serious systemic illness with a shortened life expectancy or other limitation that
             precludes participation in this trial

          9. Secondary HTN

         10. Concurrent participation in an investigational medication trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Syed Mohiuddin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton Community Health Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <results_first_submitted>August 4, 2011</results_first_submitted>
  <results_first_submitted_qc>November 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2012</results_first_posted>
  <last_update_submitted>November 6, 2012</last_update_submitted>
  <last_update_submitted_qc>November 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>African American</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
    <mesh_term>Hydralazine</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Intervention group subjects will receive education and assistance from a Community Health Center or Cardiac Center nurse practitioner or physician, health educator, dietitian, social worker, and Cardiac Center-trained community members called Community Health Advocates (CHAs).</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>No intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Intervention group subjects will receive education and assistance from a Community Health Center or Cardiac Center nurse practitioner or physician, health educator, dietitian, social worker, and Cardiac Center-trained community members called Community Health Advocates (CHAs).</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>No intervention</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="9.81"/>
                    <measurement group_id="B2" value="50" spread="11"/>
                    <measurement group_id="B3" value="49.8" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Achieving Blood Pressure Goals</title>
        <description>Percentage of subjects who achieved JNC-VII defined blood pressure goals.</description>
        <time_frame>3 month intervals</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Free antihypertensive medications, in-depth HTN and healthy living education, behavior change counseling, and Therapeutic Lifestyle Change following JNC-VII guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Free antihypertensive medications, basic hypertension education and usual clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Blood Pressure Goals</title>
          <description>Percentage of subjects who achieved JNC-VII defined blood pressure goals.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Onset Diabetes Mellitus</title>
        <time_frame>3 month intervals</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Intervention group subjects will receive education and assistance from a Community Health Center or Cardiac Center nurse practitioner or physician, health educator, dietitian, social worker, and Cardiac Center-trained community members called Community Health Advocates (CHAs).</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>No intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tammy Burns, PharmD, Research Manager</name_or_title>
      <organization>Creighton Cardiac Center</organization>
      <phone>402-280-4292</phone>
      <email>TammyBurns@creighton.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

